DOCSLIB.ORG

2019 MED-Project Annual Report

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
2019 MED-Project Annual Report 2019 MED-Project Annual Report Alameda County, California March 1, 2020 Prepared By: MED-Project LLC Submitted To: Alameda County, Department of Environmental Health Table of Contents Executive Summary ............................................................................................................. 4 Participating Producers ....................................................................................................... 5 Collection Method and Weight ............................................................................................ 5 A. Kiosks .................................................................................................................................... 5 B. Mail-Back Packages ................................................................................................................. 5 C. Take-Back Events ................................................................................................................... 5 D. Total Weight of Collected Unwanted Medicine ........................................................................... 5 Kiosk Drop-Off Locations, Mail-Back Distribution, and Take-Back Events ......................... 5 Kiosk Drop-Off Locations ......................................................................................................... 6 Mail-Back Package Distribution Locations .................................................................................. 6 Number of Mail-Back Packages Provided to Home-Bound and Under Served Residents ................ 6 Take-Back Events ................................................................................................................... 6 Disposal Information ........................................................................................................... 6 Disposal Facility Information .......................................................................................................... 6 Compliance with Plan Policies ............................................................................................. 6 Safety and Security Report ............................................................................................. 6 Educational Efforts and Public Outreach ........................................................................ 7 Public Education Activities ....................................................................................................... 7 Outreach Activities .................................................................................................................. 7 Evaluation Activities ................................................................................................................ 7 Program Goals ..................................................................................................................... 7 A. Collection Goals ...................................................................................................................... 8 B. Education and Public Outreach Goals ....................................................................................... 8 C. Collector Outreach .................................................................................................................. 8 Appendix A .............................................................................................................................. 11 List of Participating Producers ...................................................................................................... 11 Appendix B .............................................................................................................................. 37 Kiosk Drop-Off Site Locations ....................................................................................................... 37 Collection Point Collected Unwanted Products by Weight and Pick-Ups ........................................... 41 Appendix C .............................................................................................................................. 45 Mail-Back Packages Distributed Directly to Residents ..................................................................... 45 Appendix D .............................................................................................................................. 46 Take-Back Events ....................................................................................................................... 46 Appendix E .............................................................................................................................. 47 Disposal Facilities ........................................................................................................................ 47 Appendix F............................................................................................................................... 48 Plan Deviation Report .................................................................................................................. 48 Appendix G .............................................................................................................................. 50 Safety and Security Report .......................................................................................................... 50 Appendix H .............................................................................................................................. 51 MED-Project Brochure and Posters ............................................................................................... 51 Appendix I ............................................................................................................................... 66 2 MED-Project Website Pages ......................................................................................................... 66 Appendix J ............................................................................................................................... 75 Website Statistics ........................................................................................................................ 75 Appendix K .............................................................................................................................. 76 Brochure and Poster Distribution .................................................................................................. 76 Appendix L ............................................................................................................................... 77 Social Media and Promotion Activity ............................................................................................. 77 Social Media Posts ....................................................................................................................... 77 Email Blast Activity ...................................................................................................................... 84 MED-Project Website Posts .......................................................................................................... 85 Flyer Distribution......................................................................................................................... 86 Appendix M.............................................................................................................................. 87 Media Outreach Summary ........................................................................................................... 87 3 Executive Summary Regulations Sec. 15.C.i. “The purpose of the Executive Summary is to provide a broad understanding of the Plan as a whole and content for the data and information that will follow. This Summary should include a brief description of collection and disposal efforts during the reporting period. The executive summary should also include a description of proposals to improve collection efforts and challenges encountered during the reporting period, and how they will be addressed. (Security issues must be addressed separately as set forth below.)” MED-Project LLC (“MED-Project”) operates a Product Stewardship Plan for Unwanted Medicine from Households (“Plan”) in the County of Alameda (“Jurisdiction”) under the Alameda County General Ordinance Code, Chapter 6.53, the Alameda County Safe Drug Disposal Ordinance (“Ordinance”) and the Alameda County Safe Drug Disposal Regulations (“Regulations”). This 2019 County of Alameda Annual Report (“Report”) describes the activities of MED-Project between January 1, 2019, and December 31, 2019 (the “Reporting Period”) in compliance with Ordinance Section 6.53.080. All capitalized terminology not defined in this Report is derived from the approved Plan dated February 15, 2019, and amended March 27, 2019. MED-Project began collection in 2015 under the initial Plan, dated January 30, 2015, and approved on February 25, 2015. An Updated Plan was submitted on February 15, 2019, amended on March 27, 2019, and approved by the Alameda County Department of Environmental Health (the “Department”) on April 5, 2019. A notice of temporary closure of a disposal facility was sent on October 4, 2019, informing the Jurisdiction of the alternative disposal facilities to be used during the facility’s maintenance closure. The facility subsequently resumed operations in February 2020. During 2019, priority was given to performing outreach to eligible pharmacies and Law Enforcement Agencies (“LEAs”) throughout the Jurisdiction and establishing Kiosk Drop-Off
Load more

Recommended publications
  • Uniqure N.V. Paasheuvelweg 25A 1105BP Amsterdam the Netherlands +1-339-970-7000
    uniQure N.V. Paasheuvelweg 25a 1105BP Amsterdam The Netherlands +1-339-970-7000 NOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS To be held on September 14, 2017 To the Shareholders of uniQure N.V.: Notice is hereby given that an Extraordinary General Meeting of Shareholders (the “Extraordinary Meeting”) of uniQure N.V., a public company with limited liability ( naamloze vennootschap ) under the laws of the Netherlands (the “Company,” “uniQure,” and “we”), will be held on September 14, 2017, at 9:30 a.m., Central European Summer Time, at the Company’s principal executive offices located at Paasheuvelweg 25a, 1105BP Amsterdam, the Netherlands, for the following purposes: I. Opening and announcements; II. Appointment of Jeremy P. Springhorn, Ph.D. as a non-executive director (voting proposal no. 1); III. Appointment of Madhavan Balachandran as a non-executive director (voting proposal no. 2); IV Any other business that may properly come before the meeting or any adjournment of the meeting; and V. Closing of the meeting. Each person authorized to attend the Extraordinary Meeting may inspect the Agenda at the office of uniQure. Our Board of Directors (our “Board”) recommends that you vote “FOR” each of the voting proposals noted above. The record date is set at the close of business on August 17, 2017 EST and, therefore, only the Company’s shareholders of record at the close of business on August 17, 2017 EST are entitled to receive this notice (this “Notice”) and to vote at the Extraordinary Meeting and any adjournment thereof. Only shareholders who have given notice in writing to the Company by September 12, 2017 of their intention to attend the Extraordinary Meeting in person are entitled to attend the Extraordinary Meeting in person.
    [Show full text]
  • THE CROFTER, December 20131
    1 THE CROFTER, DECEMBER 20131 Scottish Crofting Federation THE CROFTER rooted in our communities The journal of the Scottish Crofting Federation, the only member-led organisation dedicated to the promotion of crofting and the largest association of small-scale food producers in the UK DECEMBER 2013 Number 101 Did the 2010 Questions on Scottish Act equalise availability of Government land sale policy OLLOWING THE Scottish Government's expressing an interest in the land, when, as crofting grants? decision to withdraw part of its Rosal the sales particulars were keen to point out, Fforest estate in Sutherland from communities were cleared from this land and open market sale after public criticism, the it is a deserted wilderness. ROFTING-SPECIFIC grants, SCF asked the government to examine its Putting this land on the market in this way is namely CCAGS and CHGS, policies on the sale of public land, community simply perpetuating a system of land ownership were expected to be extended to ownership and the creation of new crofts. concentrated into few hands, a system the C SCF chair Derek Flyn believes the Rosal Scottish people want to see changed.” owner-occupier crofters by virtue of the Crofting Reform (Scotland) Act 2010. case demonstrates some of the problems He continued “A great deal of effort and The former scheme provides grants caused by the manner in which the Forestry public money has been invested in reforming towards agricultural developments such Commission conducts the process of land crofting. The SG has pledged its commitment as sheds, barns, fencing and other sale. He said: “There is no surprise that to the crofting system and has legislated to permanent improvements; the latter local communities did not come forward Continued on page 3 towards the building of a croft house.
    [Show full text]
  • CB2013 Committee and Board Disclosureauditlist 9.10.13
    2013-2014 Conflict of Interest Disclosure AST Activity Participant First Name Participant Last Name Degree DisclosureDate Disclsoure Item Committee Member Reza Abdi MD 4/22/2013 No Relevant Financial Relationships Committee Member Sameh R. Abul-Ezz MD, PhD 4/16/2013 No Relevant Financial Relationships Committee Member Deborah B. Adey MD 4/15/2013 No Relevant Financial Relationships Committee Member Enver Akalin MD 4/16/2013 Consultant relationship with Pfizer Fellows 2013 Maria-Luisa Alegre MD, PhD 7/12/2013 No Relevant Financial Relationships Committee Member Alessandrini Alessandro PhD 4/29/2013 No Relevant Financial Relationships Board Member James S. Allan MD 5/3/2013 Committee Member No Relevant Financial Relationships Rita R. Alloway PharmD, FCCP Grant Support relationship with Astellas Grant Support relationship with BMS Grant Support relationship with Novartis Grant Support relationship with Lifecycle Grant Support relationship with Millenium Grant Support relationship with Pfizer (previously Wyeth) Grant Support relationship with Genentech (previously Roche) Board Member Grant Support relationship with Viropharma Committee Member Grant Support relationship with Alexion Fellows 2013 7/18/2013 Grant Support relationship with Sanofi (previously Genzyme, previously Sangstat) Committee Member Sandra Amaral MD, MHS 6/18/2013 Other relationship with Bristol Myers-Squibb Hatem Amer MD 5/6/2013 Grant Support relationship with Abbott Laborartories. Committee Member Other relationship with Massacheussetts Medical Society. Committee Member William Applegate No Relevant Financial Relationships Committee Member Alexander Aussi BSN, RN, MBA 4/22/2013 Consultant relationship with Total Transplant Advantage, LLC Committee Member Jamil Azzi MD 4/30/2013 No Relevant Financial Relationships Committee Member Fellows 2013 Mark L.
    [Show full text]
  • Pfizer's Bourla
    No. 3985 December 13, 2019 line success and business development. “In the next two years, we need to see how the pipeline is delivering,” he said. Bourla has been outspoken that when it comes to business development, he doesn’t see a mega-merger on the hori- zon. Instead, he said he is looking to bring in mid-stage clinical development assets to complement the internal pipeline. It sounds like investors can expect the company to be active on the business development front within those guard- rails. “I want to double it,” he said of the pipeline, which includes 92 projects right now. “And, we are going to double it by bringing in a lot of innovation to comple- ment what we distribute.” The company is focusing business de- velopment on six core therapeutic areas Pfizer’s Bourla: “I Think We Forgot as well, but Bourla indicated the company will be actively building out those areas both through internal investment and What It Looks Like To Grow” external collaboration. “We’re going to be JESSICA MERRILL [email protected] active because Pfizer is a very big plane and it cannot fly with one engine,” he said. fizer Inc. CEO Albert Bourla took in July it will merge the Upjohn business Bourla highlighted Pfizer’s recent acqui- over the top leadership spot from with Mylan NV to form a new generic drug sition of the cancer specialist Array Bio- PIan Read a year ago, but has quickly company to be called Viatris GMBH. Pharma for $11.4bn as an example of the executed on big changes poised to make The resulting Pfizer will be significantly kinds of deals the company will be pursu- Pfizer significantly smaller and faster smaller, with a 2020 annual revenue base ing.
    [Show full text]
  • Surescripts, Llc As Amicus Curiae in Support of Petitioners in No
    Nos. 19-508 and 19-825 In the Supreme Court of the United States ———————————— AMG CAPITAL MANAGEMENT, LLC, ET AL., Petitioners, v. FEDERAL TRADE COMMISSION, Respondent. ———————————— FEDERAL TRADE COMMISSION, Petitioner, v. CREDIT BUREAU CENTER, LLC, ET AL., Respondents. ———————————— ON WRITS OF CERTIORARI TO THE UNITED STATES COURTS OF APPEALS FOR THE SEVENTH AND NINTH CIRCUITS ———————————— BRIEF OF SURESCRIPTS, LLC AS AMICUS CURIAE IN SUPPORT OF PETITIONERS IN NO. 19-508 AND RESPONDENTS IN NO. 19-825 ———————————— ALFRED C. PFEIFFER, JR. ROMAN MARTINEZ LATHAM & WATKINS LLP Counsel of Record 505 Montgomery Street AMANDA P. REEVES Suite 2000 ALLYSON M. MALTAS San Francisco, CA 94111 DOUGLAS C. TIFFT BLAKE E. STAFFORD JAMES A. TOMBERLIN* LATHAM & WATKINS LLP 555 Eleventh Street, NW Suite 1000 Washington, DC 20004 (202) 637-2200 [email protected] Counsel for Amicus Curiae Surescripts, LLC TABLE OF CONTENTS Page TABLE OF AUTHORITIES ...................................... ii INTEREST OF AMICUS CURIAE ............................1 SUMMARY OF ARGUMENT .....................................3 ARGUMENT ...............................................................5 I. The FTC Has Increasingly Wielded Section 13(b) To Obtain Monetary Relief In Antitrust Cases ................................................5 II. The FTC’s Antitrust Authority Confirms That Section 13(b) Does Not Authorize Monetary Relief ..................................................22 CONCLUSION ..........................................................32 ii TABLE OF AUTHORITIES Page(s) CASES Apple Inc. v. Pepper, 139 S. Ct. 1514 (2019) .......................................... 13 Armstrong v. Exceptional Child Center, Inc., 575 U.S. 320 (2015) .............................................. 23 Bell Atlantic Corp. v. Twombly, 550 U.S. 544 (2007) .............................................. 26 In re Cardinal Health, Inc., No. 101-0006, 2015 WL 1849040 (F.T.C. Apr. 17, 2015) ........................ 19, 20, 28, 30 Credit Suisse Securities (USA) LLC v. Billing, 551 U.S.
    [Show full text]
  • Health Industry Business Communications Council
    Health Industry Business Communications Council Registered Labelers: Accredited Auto-ID Labeling Standards Argentina New MedTek Devices Pty Ltd Oxavita SRL Norseld Pty Ltd. Novadien Healthcare Pty Ltd The following companies Odontit S.A. (and/or their subsidiaries/ PAMPAMED S.R.L. Numedico Technologies Pty Ltd divisions) have applied PATEJIM SRL Opto Global Pty. Ltd. for a Labeler Identification Orthocell Limited Code (LIC) assignment with Austria Prolotus Technologies Pty Ltd HIBCC*. By doing so, they afreeze GmbH Red Milawa Pty Ltd dba Magic Mobility have demonstrated their AMI GmbH SDI Limited commitment to patient safety Bender Medsystems GmbH Signostics Ltd. and logistical efficiency for BHS Technologies GmbH Sirtex Medical Pty Ltd their customers, the industry Metasys Medizintechnik GmbH Smith & Nephew Surgical Pty. Ltd. and the public at large. PAA Laboratories GmbH Staminalift International Limited Safersonic Medizinprodukte Handels The Pipette Company Pty. Ltd. Any organization that is GmbH Thermo Electron Corporation interested in using the HIBC W & H Dentalwerk Burmoos GmbH Vush Pty Ltd uniform labeling system may apply for the assignment of VUSH STIMULATION Australia one or more LICs. William A Cook Australia Pty. Ltd. Adv. Surgical Design & Manufacture, Ltd. Last updated 9-21-2021 AirPhysio Pty Ltd Belgium Annalise-AI Pty Ltd 3M Europe Apollo Medical Imaging Technology Pty Advanced Medical Diagnostics SA/NV Ltd Analis SA/NV Benra Pty Ltd dba Gelflex Laboratories Baxter World Trade Bioclone Australia Pty. Ltd. Bio-Rad RSL Candelis, Inc. Bio-Rad Lab Inc Clinical Diag. Group DePuy Australia Pty. Ltd. Biosource Europe SA For more information, please dorsaVi Ltd Cilag NV contact the HIBCC office at: EC Certification Service GmbH Coris Bioconcept Fink Engineering Pty Ltd Fuji Hunt Photographic Chemicals NV 2525 E.
    [Show full text]
  • Federal Register/Vol. 84, No. 232/Tuesday, December 3, 2019
    Federal Register / Vol. 84, No. 232 / Tuesday, December 3, 2019 / Notices 66191 the Assistant Attorney General, patterns, devices, manufacturing filed with and accepted, subject to final developed the HSR Rules and the processes, or customer names. approval, by the Commission, has been corresponding Notification and Report placed on the public record for a period Form. Heather Hippsley, of thirty (30) days. The following On September 11, 2019, the Deputy General Counsel. Analysis to Aid Public Comment Commission sought comment on the [FR Doc. 2019–26075 Filed 12–2–19; 8:45 am] describes the terms of the consent reporting requirements associated with BILLING CODE 6750–01–P agreement and the allegations in the the HSR Rules and corresponding complaint. An electronic copy of the Notification and Report Form. 84 FR full text of the consent agreement 47951. No relevant comments were FEDERAL TRADE COMMISSION package can be obtained from the FTC received. Pursuant to the OMB [File No. 191 0061] Home Page (for November 15, 2019), on regulations, 5 CFR part 1320, that the World Wide Web, at https:// implement the PRA, 44 U.S.C. 3501 et Bristol-Myers Squibb Company and www.ftc.gov/news-events/commission- seq., the FTC is providing this second Celgene Corporation; Analysis of actions. opportunity for public comment while Agreement Containing Consent Orders You can file a comment online or on seeking OMB approval to renew the pre- To Aid Public Comment paper. For the Commission to consider existing clearance for those information your comment, we must receive it on or collection requirements.
    [Show full text]
  • RHS Supreme Champions 2017
    RHASS MAGAZINE SUMMER 2017 What a ShowStoppER! RHS Supreme Champions 2017: 8-page pullout + Post-Show Overview + New Members’ Area Survey + Technical Innovation Awards + Exhibitors Stories + RHASS Directors and Presidential Team 2017-18 + RHET Latest News + RHC Events to look out for RHASS • Society Magazine • Summer 2017 | 1 6 Contents COVER STORIES 6 Post-Show Overview 21 RHET News 24 RHC Events 13 26 RHASS Directors and Officials 2017 28 RHASS Presidential Team FEATURES 3 Welcome - Alan Laidlaw, Chief Executive 4 News Update 6 Royal Highland Show - Post-Show Analysis 21 8 Case Studies - “What the Royal Highland Show means to me...” 10 Technical Innovation Awards 13 Supreme Champions 2017 Pullout 21 Royal Highland Education Trust News 24 Royal Highland Centre Events 30 Members’ Feedback 24 RHASS MAGAZINE SUMMER 2017 CONTACT DETAILS: RHASS Society magazine Written & produced by is published by: The Royal Highland and Represent Agricultural Society of Scotland, Royal Highland 57 Calton Road, Centre, Ingliston, Edinburgh EH28 8NB Edinburgh EH8 8FJ Tel: (0131) 335 6200 [email protected] What a Email: [email protected] ShowStoppER! Web: www.rhass.org.uk RHS Supreme Champions 2017: 8-page pullout + Post-Show Overview + New Members’ Area Survey + Technical Innovation Awards + Exhibitors Stories Charity No. SC4561 + RHASS Directors and Presidential Team 2017-18 + RHET Latest News + RHC Events to look out for RHASS • Society Magazine • Summer 2017 | 1 2 | RHASS • Society Magazine • Summer 2017 Over 8,000 members attended the Show on each of the four days Welcome from RHASS Chief Executive Alan Laidlaw t is with pride that I reflect on my first Show as Chief Executive.
    [Show full text]
  • Shire Acquisition of Viropharma - Strategic Move to Strengthen Shire’S Rare Disease Business - Augments Already Strong Growth Prospects
    Shire acquisition of ViroPharma - Strategic move to strengthen Shire’s Rare Disease business - Augments already strong growth prospects Flemming Ornskov, MD Chief Executive Officer Graham Hetherington Chief Financial Officer Our purpose We enable people with life-altering conditions to lead better lives. CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS Statements included in this communication that are not historical facts are forward-looking statements. Forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, results could be materially adversely affected. The risks and uncertainties include, but are not limited to, that: •Shire’s proposed acquisition of ViroPharma may not be consummated due to the occurrence of an event, change or other circumstances that gives rise to the termination of the merger agreement; •a governmental or regulatory approval required for the proposed acquisition of ViroPharma may not be obtained, or may be obtained subject to conditions that are not anticipated, or another condition to the closing of the proposed acquisition may not be satisfied; •ViroPharma may be unable to retain and hire key personnel and/or maintain its relationships with customers, suppliers and other business partners pending the consummation of the proposed acquisition by Shire, or ViroPharma’s business may be disrupted by the proposed acquisition, including increased costs and diversion of management time and resources; •difficulties in integrating ViroPharma into Shire may lead to the combined company not being able to realize the expected operating efficiencies, cost savings, revenue enhancements, synergies or other benefits at the time anticipated or at all; and risks and uncertainties detailed from time to time in Shire’s or ViroPharma’s filings with the U.S.
    [Show full text]
  • Register of GDP Sites 2019
    Register of GDP Sites 2019 Updated 16 August 2019 There are other sites authorised for wholesale dealing of veterinary medicinal products which do not appear on this register. These sites wholesale deal in both human and veterinary medicinal products and can be found on the MHRA section of GOV.UK: https://www.gov.uk/government/publications/human-and-vetinary-medicines- register-of-licensed-wholesale-distribution-sites-december-2014 Register of Authorised Wholesale Dealer Sites Authorisation Holder: WDA33618 ABBEYVET LLP 310 CHESTER ROAD, HARTFORD, NORTHWICH, CHESHIRE, CW8 2AB SITE ID: S0415 ABBEYVET LLP 310 CHESTER ROAD, HARTFORD, NORTHWICH, CHESHIRE, CW8 2AB SITE ID: S0010 ABBEYVET LLP SHERBURN ENTERPRISE PARK, SHERBURN IN ELMET, LEEDS, WEST YORKSHIRE, LS25 6NB Authorisation Holder: WDA8599 AGRIHEALTH (N.I.) LIMITED 9 SILVERWOOD INDUSTRIAL AREA, SILVERWOOD ROAD, LURGAN, CRAIGAVON, COUNTY ARMAGH, BT66 6LN SITE ID: S0015 AGRIHEALTH (N.I.) LIMITED 9 SILVERWOOD INDUSTRIAL AREA, SILVERWOOD ROAD, LURGAN, CRAIGAVON, COUNTY ARMAGH, BT66 6LN Authorisation Holder: WDA5097 ALBAVET LIMITED BUSINESS INCUBATOR OFFICE 21, MYREGORMIE PLACE, MITCHELSTON INDUSTRIAL ESTATE, KIRKCALDY, FIFE, KY1 3NA SITE ID: S0456 ALBAVET LIMITED BUSINESS INCUBATOR OFFICE 21, MYREGORMIE PLACE, MITCHELSTON INDUSTRIAL ESTATE, KIRKCALDY, FIFE, KY1 3NA SITE ID: S0525 CVS GROUP PLC CVS HOUSE, OWEN ROAD, DISS, NORFOLK, IP22 4ER Authorisation Holder: WDA5030 ALBERT E JAMES & SON LIMITED BARROW MILL BARROW STREET, BARROW GURNEY, BRISTOL, BS48 3RU SITE ID: S0303 ALBERT E JAMES &
    [Show full text]
  • Package Insert Has Been Approved by the U.S
    HIGHLIGHTS OF PRESCRIBING INFORMATION **Doses up to 1,000 U every 3 to 4 days may be considered based on These highlights do not include all the information needed to use individual patient response. ® CINRYZE safely and effectively. See full prescribing information for ---------------------- DOSAGE FORMS AND STRENGTHS -------------------- CINRYZE. Approximately 500 Units (lyophilized) in an 8 mL vial. (3) CINRYZE (C1 Esterase Inhibitor [Human]) ---------------------------- CONTRAINDICATIONS ------------------------------- For Intravenous Use, Freeze-Dried Powder for Reconstitution Patients who have manifested life-threatening immediate hypersensitivity Initial U.S. Approval: 2008. reactions, including anaphylaxis, to the product (4). --------------------------- RECENT MAJOR CHANGES -------------------------- ----------------------------- WARNINGS/PRECAUTIONS ------------------------ • Indications and Usage (1) 06/2018 • Hypersensitivity reactions may occur. Have epinephrine immediately • Dosage and Administration (2.1) 06/2018 available for treatment of acute severe hypersensitivity reaction (5.1) • --------------------------- INDICATIONS AND USAGE --------------------------- Serious arterial and venous thromboembolic (TE) events have been CINRYZE is a C1 esterase inhibitor indicated for routine prophylaxis against reported at the recommended dose of C1 Esterase Inhibitor (Human) angioedema attacks in adults, adolescents and pediatric patients (6 years of products, including CINRYZE, following administration in patients with age and older)
    [Show full text]
  • Representative Legal Matters Randall B
    Representative Legal Matters Randall B. Sunberg H. Lundbeck A/S in the licensing to Denovo Biopharma of global rights to idalopirdine (an oral 5-HT6 antagonist) for Alzheimer's Disease, schizophrenia and other indications, subject to options for Lundbeck to re-acquire such rights with the parties sharing China rights. Takeda in its strategic collaboration with KSQ Therapeutics to identify optimal T cell and NK cell gene targets screened using KSQ’s CRISPRomics technology and to develop and commercialize novel cell and non-cell immuno-oncology therapies. NBE Therapeutics in its collaboration with Exelixis to discover and develop antibody-drug conjugates for oncology applications. Takeda in the sale to Neuraxpharm of global rights to the prescription brand Buccolam® (indicated for the emergency treatment of epileptic children with prolonged acute convulsive seizures). BeiGene in its collaboration with Assembly Biosciences to develop and commercialize in China, Hong Kong, Macau and Taiwan Assembly’s portfolio of three clinical-stage core inhibitor candidates for the treatment of patients with chronic hepatitis B virus (HBV) infection. GSK Consumer Healthcare in its collaboration with Mammoth Biosciences to develop a rapid, handheld CRISPR-based test to detect novel coronavirus infections. H. Lundbeck A/S in the acquisition of Alder BioPharmaceuticals, Inc, a company committed to migraine treatment and prevention, a transaction valued at USD 1.95 billion. Galapagos in its transformative USD 5.1 billion research and development collaboration
    [Show full text]